The complement C4 test measures the blood concentration of complement component 4, a protein used early in the classical and lectin complement pathways. C4 is frequently ordered with C3 because the two results can reveal different patterns of immune activation. A low C4 may occur when antibody-containing immune complexes consume complement, when C1 inhibitor does not adequately control pathway activation, when protein production or retention is impaired, or when a person inherits fewer functional C4 genes. A high result is usually less specific and may reflect inflammation or increased protein production.
C4 is useful in the evaluation and monitoring of systemic lupus erythematosus, selected kidney diseases, cryoglobulinemia, hereditary or acquired C1 inhibitor deficiency, and rare complement disorders. It cannot confirm any of these conditions by itself. The most accurate interpretation combines the exact laboratory range with C3, CH50, C1 inhibitor tests, symptoms, organ-specific findings, medicines, and previous values. This guide explains what high, low, and normal C4 results can—and cannot—mean.
- Routine C4 testing measures protein concentration, not necessarily C4 function or active split products.
- Low C4 with low C3 often suggests classical-pathway consumption; low C4 with normal C3 creates a different differential diagnosis.
- C4 is an important screening clue in C1 inhibitor deficiency, but a normal C4 does not absolutely exclude hereditary angioedema.
- C4 trends can support lupus monitoring, although direct kidney and clinical findings remain essential.
- High C4 is usually a nonspecific acute-phase response rather than a stand-alone disease marker.
Table of Contents
- Where C4 fits in the complement cascade
- How to read a C4 laboratory report
- Major patterns behind a low C4 result
- C4 in hereditary and acquired angioedema
- C4 in lupus, vasculitis, and immune-complex disease
- High C4 and the limits of a normal result
- Interpreting C4 with C3 and functional complement tests
- What happens after an abnormal C4 result
Where C4 fits in the complement cascade
Complement is a network of soluble and cell-bound proteins that recognizes danger, marks targets for removal, recruits inflammatory cells, and helps damage susceptible microbes. Three major activation routes—the classical, lectin, and alternative pathways—feed into a common sequence involving C3, C5, and the terminal membrane attack complex.
C4 participates in the classical and lectin pathways. In the classical pathway, the C1 complex is activated after C1q recognizes antibody-coated targets or certain molecular patterns. Activated C1s cleaves C4 into C4a and C4b. C4b attaches to a nearby surface and joins C2 to form the classical C3 convertase. The lectin pathway uses different recognition molecules and enzymes, but it also cleaves C4 and forms the same type of C3 convertase.
This position makes C4 a useful clue. Classical-pathway activation by immune complexes can lower C4. Lectin-pathway activation may also consume it. Alternative-pathway activation, in contrast, can lower C3 while leaving C4 relatively unchanged because C4 is not required to begin that route.
The routine laboratory test generally measures intact C4 antigen concentration by nephelometry or a related immunochemical method. It does not directly measure the amount of C4 being activated, the function of every C4 molecule, or tissue deposition. Specialized tests can measure C4 function, C4 activation fragments, C4d, or genetic copy number, but these answer different questions and are not substitutes for the routine result.
C4 biology is also genetically complex. Humans have C4A and C4B genes within the major histocompatibility complex, and the number of gene copies varies among people. Lower copy number can produce a naturally lower baseline, while certain C4 configurations are associated with autoimmune susceptibility. This helps explain why some people have persistently low C4 without an acute flare and why a personal baseline can be more informative than one isolated result.
For pathway interpretation, C4 is often paired with a C3 test. The CH50 test assesses whether the classical and terminal sequence can complete a functional reaction. These measurements overlap in clinical use but should not be treated as interchangeable.
How to read a C4 laboratory report
Start with the performing laboratory’s reference interval. One large reference laboratory reports 14–40 mg/dL for serum C4, but intervals differ by method, population, unit, and sometimes age. Another laboratory may use a range such as 10–40 mg/dL or report grams per liter. A result should be labeled high or low only against the range printed on that report.
The numeric value matters more than the flag alone. A C4 of 13 mg/dL may be just below one laboratory’s lower limit but within another’s. A decline from 28 to 15 mg/dL can be clinically meaningful for a person with lupus even if both values remain within a broad local interval. Conversely, a long-standing value of 12–14 mg/dL may reflect an individual baseline rather than new consumption.
Confirm the test identity. “Complement C4” usually means antigen concentration. “C4 functional,” “C4d,” “C4 activation product,” “C4 gene copy number,” and “C4 nephritic factor” are different tests. C4 is also distinct from C4d staining in tissue, which pathologists use in settings such as transplant evaluation or selected immune-mediated diseases.
Routine preparation is simple. A healthcare professional draws blood from a vein, and fasting is generally unnecessary unless another ordered test requires it. Laboratories set their own instructions for centrifugation, storage, and transport. Severe lipemia can interfere with some optical assays. If the result conflicts strongly with the rest of the evaluation, the laboratory can advise whether specimen quality or analytical interference is plausible.
When monitoring disease, try to use the same laboratory. A change in assay platform or reference range can look like a biological change. Keep copies of the actual numbers, units, and intervals rather than tracking only “L” and “H” symbols.
Medication and treatment timing belongs on the interpretation checklist. Immunosuppressive therapy can reduce immune-complex consumption. Plasma products may temporarily add complement proteins. Complement inhibitors primarily change functional activity but can also alter activation and measured fragments. Estrogen exposure, infection, pregnancy, surgery, and major inflammation may shift production or consumption. None of these factors should prompt a patient to stop treatment without medical direction.
Major patterns behind a low C4 result
Low C4 is a mechanism, not a diagnosis. The result can arise from increased use, low inherited baseline, reduced production, protein loss, or a rare component defect.
Classical-pathway consumption
Antibody-antigen complexes can activate C1 and consume C4. This mechanism is common in active systemic lupus erythematosus and other immune-complex disorders. C3 may also be low, CH50 may fall, and disease-specific findings may change at the same time. The strength of the inference depends on the whole pattern: low C4 plus new proteinuria, active urine sediment, rising anti-dsDNA antibodies, and lupus symptoms is more informative than low C4 alone.
Cryoglobulinemia often produces a strikingly low C4, sometimes with a less pronounced C3 reduction. Cryoglobulins are immunoglobulins that precipitate under cooler conditions and can form immune complexes that activate the classical pathway. Symptoms may include purpura, neuropathy, joint pain, weakness, or kidney disease. Proper cryoglobulin collection requires warm handling before serum separation, so C4 cannot replace the technically demanding confirmatory test.
Certain infections, endocarditis, immune-complex glomerulonephritis, and selected autoimmune vasculitides can also consume C4. The clinician must investigate the cause rather than assume every low value represents lupus.
Uncontrolled C1 activation
C1 inhibitor restrains proteases in the complement and contact systems. When C1 inhibitor concentration or function is low, C4 can be chronically consumed. This is the laboratory basis for using C4 as part of the evaluation of recurrent bradykinin-mediated angioedema. The detailed interpretation differs for hereditary and acquired disease and is discussed separately below.
Genetically lower C4 concentration
C4A and C4B copy number varies. A person with fewer copies may have a persistently lower serum C4. Complete C4 deficiency is rare; partial deficiency is more common and may increase susceptibility to immune-complex autoimmunity or infection. A low inherited baseline can coexist with lupus, which complicates flare monitoring because the level may remain low even when disease is controlled.
Clues to a constitutional low baseline include similar results over many years, absence of parallel changes in C3 or symptoms, and family findings. Genetic testing is not routinely needed for every mildly low result. It becomes more relevant when functional studies, infection history, early autoimmunity, or a specialist assessment suggests a true inherited defect.
Reduced synthesis and protein loss
Severe liver dysfunction can reduce production of complement proteins. Nephrotic protein loss, protein-losing enteropathy, extensive burns, and severe malnutrition can lower C4 along with albumin and other proteins. In these settings, a broad protein pattern is expected. Liver tests, albumin, total protein, urine protein, and gastrointestinal evaluation help identify the mechanism.
Temporary or analytical variation
Biological levels fluctuate. A borderline low result may normalize after an intercurrent illness or differ when repeated on another assay. Sample problems are less notorious for C4 antigen than for functional complement tests, but no laboratory measurement is immune to interference. Confirmation is reasonable when a mild abnormality is unexpected or would trigger extensive investigation.
C4 in hereditary and acquired angioedema
C4 is one of the most useful initial laboratory clues in angioedema caused by C1 inhibitor deficiency. It is not the mediator of swelling. The swelling is driven mainly by excess bradykinin generated through uncontrolled contact-system activation. C4 becomes low because inadequate C1 inhibitor also permits ongoing activation of early complement proteins.
In hereditary angioedema due to C1 inhibitor deficiency, attacks often begin in childhood or adolescence, although onset varies. Swelling typically affects the skin, gastrointestinal tract, or upper airway and usually occurs without hives. Type I disease has low C1 inhibitor antigen and low function. Type II has normal or elevated antigen but low function. C4 is usually low in both, during and between attacks.
A low C4 supports suspicion but does not determine the type. Diagnosis requires the C1 esterase inhibitor antigen test and C1 esterase inhibitor function test, ideally repeated to confirm an abnormal pattern. Age, family history, symptoms, and medication exposure matter. A normal C4 cannot absolutely exclude HAE, particularly when clinical suspicion is strong or testing conditions are uncertain. Guidelines therefore recommend measuring C4, C1 inhibitor protein, and C1 inhibitor function rather than using C4 as the sole gatekeeper.
In acquired C1 inhibitor deficiency, attacks more often begin later in life and family history is absent. C4 and C1 inhibitor function are low, C1 inhibitor antigen may be low or sometimes normal, and C1q is frequently reduced. A low C1q test supports an acquired mechanism in the appropriate context. Associated conditions can include monoclonal gammopathy, lymphoproliferative disease, or autoantibodies against C1 inhibitor.
Angiotensin-converting enzyme inhibitor–associated angioedema and hereditary angioedema with normal C1 inhibitor usually have normal C4 and normal C1 inhibitor measurements. Allergic or mast-cell-mediated angioedema can also have normal complement and is more likely to include hives, itching, or rapid response to antihistamine, although clinical overlap exists.
Any tongue, throat, voice, or breathing involvement is an emergency regardless of laboratory results. A person with diagnosed bradykinin-mediated angioedema should follow the prescribed attack plan and seek emergency help. Waiting for C4 results is unsafe when the airway may be threatened.
C4 in lupus, vasculitis, and immune-complex disease
C4 is commonly measured in systemic lupus erythematosus because autoantibody-containing immune complexes activate the classical pathway. Low C4 can support a lupus diagnosis when combined with compatible clinical features and other immunologic evidence, and it can contribute to disease-activity assessment. It is neither sufficiently specific nor sufficiently sensitive to stand alone.
In some lupus flares, C3 and C4 fall together. In others, C4 falls more prominently, remains chronically low, or does not change. Production may increase during inflammation at the same time consumption accelerates. Genetic C4 copy number can also influence the baseline. For these reasons, a clinician compares the current value with the patient’s established pattern and with direct evidence of organ involvement.
Lupus nephritis monitoring should include urine protein quantification, urinalysis with sediment, serum creatinine/eGFR, and blood pressure. Anti-dsDNA antibodies, C3, and C4 provide immunologic context. A low C4 may strengthen concern when proteinuria or urinary blood is worsening, but a normal C4 does not exclude active nephritis. Kidney biopsy may be needed to identify the histologic class, activity, and chronic damage and to guide treatment.
In cryoglobulinemic vasculitis, C4 can be very low because circulating immune complexes activate the classical pathway. Hepatitis C, autoimmune disease, and B-cell or plasma-cell disorders are possible underlying causes. The evaluation may include cryoglobulins, rheumatoid factor, hepatitis testing, monoclonal-protein studies, urinalysis, kidney function, and tissue biopsy. C4 helps recognize the pattern but cannot identify the cause.
Low C4 may also appear in immune-complex disease related to infection, including infective endocarditis, or in certain glomerulonephritides. Fever, weight loss, heart murmur, embolic phenomena, blood-culture findings, and imaging can be more urgent than the complement abnormality. Immunosuppression can be harmful if an infection is mistakenly treated as primary autoimmunity.
Rheumatoid arthritis alone does not consistently cause low serum C4. Reduction is more concerning when there is systemic immune-complex activity, vasculitis, cryoglobulinemia, or another complication. Similarly, a low result in someone with joint pain and a positive ANA does not establish lupus; ANA positivity is common and must be interpreted by titer, pattern, symptoms, and more specific antibodies.
High C4 and the limits of a normal result
C4 can increase as part of an acute-phase response. Infection, tissue injury, chronic inflammatory signaling, obesity, metabolic syndrome, and some malignancies may raise the concentration. A high C4 result is usually nonspecific and rarely identifies a single condition.
In a patient whose C4 was low because of active immune-complex disease, movement back toward the reference interval may support improvement. The conclusion is strongest when symptoms, urine findings, kidney function, and other biomarkers improve too. A rebound above range does not necessarily indicate excessive complement activity requiring treatment.
High antigen concentration does not prove normal function. Rarely, a protein can be present but functionally impaired. If recurrent severe infections or a characteristic pathway-screening pattern suggests complement deficiency, functional testing remains appropriate despite a normal or high C4 concentration.
A normal C4 also has important limits:
- It does not rule out systemic lupus erythematosus or an active flare.
- It does not rule out lupus nephritis when urine or kidney findings are abnormal.
- It does not absolutely exclude hereditary angioedema due to C1 inhibitor deficiency.
- It does not evaluate alternative-pathway activation, which may lower C3 without lowering C4.
- It does not show whether complement is being activated locally inside tissue.
- It does not replace C1 inhibitor function, CH50, AH50, or disease-specific tests.
Context can create a “normal” concentration despite active use. Because C4 production rises during inflammation, increased synthesis may offset consumption. A person with a high genetic baseline may experience a substantial decline that remains within the population range. This is why trends and paired results often matter more than a simple normal/abnormal label.
Interpreting C4 with C3 and functional complement tests
No pattern is absolute, but combinations help prioritize explanations.
| C4 | C3 | Functional or clinical context | Possibilities to consider |
|---|---|---|---|
| Low | Low | Low CH50, lupus symptoms, abnormal urine | Classical-pathway immune-complex consumption |
| Low | Normal | Low C1 inhibitor function or recurrent non-itchy swelling | C1 inhibitor deficiency, especially HAE or acquired angioedema |
| Very low | Normal or mildly low | Purpura, neuropathy, hepatitis risk, positive rheumatoid factor | Cryoglobulinemic immune-complex disease |
| Low | Normal | Stable for years, no active symptoms | Genetic low C4 baseline or partial deficiency |
| Normal | Low | Abnormal AH50, hematuria or proteinuria | Alternative-pathway activation or selected kidney disorders |
| Normal | Normal | Absent CH50 | Early classical or terminal component functional defect, treatment effect, or specimen problem |
| High | High or normal | Infection, obesity, metabolic inflammation | Nonspecific acute-phase production |
CH50 requires C1 through C9 to work in sequence. If CH50 is extremely low while C3 and C4 antigen concentrations are normal, the issue may be a functional defect in another component, a nonfunctional protein, complement-blocking therapy, or preanalytical degradation. AH50 helps determine whether the alternative pathway and shared terminal sequence are intact.
When both CH50 and AH50 are low, clinicians consider a shared terminal component defect, severe consumption, targeted complement inhibition, or sample handling. When CH50 is low and AH50 is normal, an early classical component—including C1, C2, or C4—becomes more likely. Individual component assays then localize the problem.
C4 levels can also be influenced by complement genetics. If the main concern is a hereditary deficiency, concentration, function, pathway screens, infection phenotype, family history, and molecular testing must align. A single antigen measurement cannot distinguish a harmless low copy-number baseline from a clinically significant functional defect.
What happens after an abnormal C4 result
The next step should answer the original clinical question rather than chase the number in isolation.
For suspected lupus or immune-complex disease, clinicians commonly review C3, CH50, ANA, anti-dsDNA, blood counts, urine protein, urine sediment, creatinine/eGFR, liver tests, and symptoms. Testing for cryoglobulins, hepatitis, monoclonal proteins, or infection is added when the phenotype suggests those causes.
For recurrent angioedema without hives, C1 inhibitor antigen and function are central. C1q helps assess acquired deficiency. Abnormal results are usually repeated for confirmation, especially before assigning a lifelong hereditary diagnosis. Testing during an attack can be informative, but patients should not provoke or delay treatment of an attack to obtain bloodwork.
For recurrent invasive infections, CH50 and AH50 establish whether a pathway is functionally impaired. Profound or persistent abnormalities warrant clinical immunology consultation. The specialist may order individual component function, genetic testing, vaccine-response studies, and a prevention plan tailored to the defect.
For a borderline isolated low C4, repeating the test at the same laboratory may be sufficient. A clinician may also review whether the person has always run low. The value of repetition is greatest when it will distinguish a transient change from a persistent pattern or when a trend will influence treatment.
Patients can improve the visit by bringing prior laboratory reports, a complete medication list, dates of infections or swelling episodes, family history, and details of urine or kidney changes. Useful questions include: Is my C4 low by itself or with C3? Could this be my baseline? Does the pattern suggest consumption, C1 inhibitor deficiency, loss, or inherited deficiency? Which additional result would change management?
Do not start supplements or change immune, blood-pressure, or angioedema medication to “raise C4.” There is no general C4-boosting treatment. Management targets the underlying disease.
Seek urgent care for airway swelling, breathing or swallowing difficulty, confusion, a rapidly spreading rash with fever, severe headache and neck stiffness, markedly reduced urine output, rapidly worsening edema, or severe hypertension symptoms. These emergencies are defined by the clinical condition, not by how high or low C4 appears on the report.
References
- Complement C4, Serum. 2026. Laboratory test guidance.
- Complement component 4. 2025. U.S. National Library of Medicine medical encyclopedia.
- Complement in systemic lupus erythematosus across time and space. 2025. Review article.
- 2024 American College of Rheumatology Guideline for Screening, Treatment, and Management of Lupus Nephritis. 2025. Clinical practice guideline.
- Immunodeficiency: Complement disorders. 2024. Clinical review.
- The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update. 2022. International clinical guideline.
Disclaimer
This article is educational and does not replace medical evaluation, diagnosis, or treatment. C4 must be interpreted with the performing laboratory’s range, related complement tests, symptoms, medications, and organ-specific findings. Seek emergency care for throat or tongue swelling, breathing difficulty, severe infection symptoms, or signs of rapidly worsening kidney disease.
